GlobeNewswire Inc | Nov 18, 2020 10:16AM EST

November 18, 2020

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.

The acquisition takes Mr Cerrone's interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

1. Details of PDMR / person closely associateda) Name Gabriele Cerrone

2. Reason for the notification

a) Position / status Executive Chairman

b) Initial notification /amendment Initial notification

3. Details of the issuer

a) Name Tiziana Life Sciences plc

b) LEI 213800CED47HI8PIOB36

Details of the transaction(s): section to be repeated for (i) each type of4. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the financiala) instrument Ordinary Shares of 3p each

Identification code of the Financial ISIN for Tiziana Life Sciences plc:b) Instrument GB00BKWNZY55

c) Nature of the transaction Market Purchase

84pd) Price(s) and volume(s) 45,000f) Date of the transaction 18 November 2020

g) Place of the transaction XLON

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohns Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohns Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc +44 (0)20 7495 2379Gabriele Cerrone, Chairman and founder Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880Liam Murray / Jo Turner Optiva Securities Limited (Broker) + 44 (0)20 3981 4173Robert Emmet

United States Investors:

Dave Gentry Office 1 800 RED CHIP (733 2447)RedChip Companies Inc. Cell 407-491-4498 (USA) dave@redchip.com